Front Row Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.48M | Buy |
25,204
+66
| +0.3% | +$14.6K | 1.85% | 9 |
|
|
2025
Q4 | $5.74M | Sell |
25,138
-328
| -1% | -$74.7K | 1.91% | 7 |
|
|
2025
Q3 | $5.9M | Sell |
25,466
-349
| -1% | -$71.1K | 1.98% | 7 |
|
|
2025
Q2 | $4.79M | Sell |
25,815
-263
| -1% | -$48.9K | 1.67% | 10 |
|
|
2025
Q1 | $5.46M | Sell |
26,078
-878
| -3% | -$171K | 2.1% | 8 |
|
|
2024
Q4 | $4.79M | Sell |
26,956
-116
| -0.4% | -$21.3K | 1.65% | 9 |
|
|
2024
Q3 | $5.35M | Sell |
27,072
-274
| -1% | -$51.1K | 1.91% | 8 |
|
|
2024
Q2 | $4.69M | Buy |
27,346
+265
| +1% | +$43.9K | 1.63% | 10 |
|
|
2024
Q1 | $4.93M | Buy |
27,081
+269
| +1% | +$46.4K | 1.83% | 10 |
|
|
2023
Q4 | $4.16M | Sell |
26,812
-426
| -2% | -$62.1K | 1.91% | 9 |
|
|
2023
Q3 | $4.06M | Sell |
27,238
-507
| -2% | -$74.4K | 1.87% | 7 |
|
|
2023
Q2 | $3.74M | Buy |
27,745
+39
| +0.1% | +$5.72K | 1.66% | 8 |
|
|
2023
Q1 | $4.42M | Buy |
27,706
+318
| +1% | +$48.6K | 2.12% | 6 |
|
|
2022
Q4 | $4.43M | Sell |
27,388
-1,099
| -4% | -$169K | 2.29% | 4 |
|
|
2022
Q3 | $3.82M | Sell |
28,487
-83
| -0.3% | -$11.9K | 1.98% | 6 |
|
|
2022
Q2 | $4.38M | Sell |
28,570
-185
| -0.6% | -$28.3K | 2.15% | 5 |
|
|
2022
Q1 | $4.66M | Buy |
28,755
+40
| +0.1% | +$5.81K | 1.88% | 6 |
|
|
2021
Q4 | $3.89M | Buy |
28,715
+857
| +3% | +$101K | 1.45% | 12 |
|
|
2021
Q3 | $3M | Sell |
27,858
-43
| -0.2% | -$4.91K | 1.27% | 16 |
|
|
2021
Q2 | $3.29M | Buy |
27,901
+385
| +1% | +$43.4K | 1.35% | 13 |
|
|
2021
Q1 | $2.98M | Buy |
27,516
+1,024
| +4% | +$110K | 1.44% | 11 |
|
|
2020
Q4 | $2.84M | Sell |
26,492
-323
| -1% | -$31K | 1.45% | 11 |
|
|
2020
Q3 | $2.81M | Sell |
26,815
-668
| -2% | -$62.9K | 1.49% | 8 |
|
|
2020
Q2 | $2.7M | Sell |
27,483
-415
| -1% | -$36.5K | 1.67% | 7 |
|
|
2020
Q1 | $2.29M | Buy |
27,898
+1,725
| +7% | +$147K | 1.55% | 10 |
|
|
2019
Q4 | $2.32M | Sell |
26,173
-1,261
| -5% | -$105K | 1.51% | 9 |
|
|
2019
Q3 | $2.08M | Sell |
27,434
-431
| -2% | -$29.5K | 1.48% | 10 |
|
|
2019
Q2 | $2.03M | Buy |
27,865
+267
| +1% | +$21K | 1.48% | 11 |
|
|
2019
Q1 | $2.22M | Buy |
27,598
+590
| +2% | +$48.3K | 1.73% | 8 |
|
|
2018
Q4 | $2.49M | Sell |
27,008
-587
| -2% | -$51.6K | 2.17% | 4 |
|
|
2018
Q3 | $2.19K | Sell |
27,595
-245
| -0.9% | -$23.2K | 1.54% | 9 |
|
|
2018
Q2 | $2.59K | Buy |
27,840
+119
| +0.4% | +$11.6K | 1.66% | 7 |
|
|
2018
Q1 | $2.62M | Sell |
27,721
-82
| -0.3% | -$9.01K | 1.84% | 6 |
|
|
2017
Q4 | $2.69M | Buy |
+27,803
| New | +$2.62M | 2.14% | 4 |
|
Other funds holding ABBV
VCM
VPM
Front Row Advisors's ABBV Position: Q1 2026 in Review
Front Row Advisors increased its AbbVie (ABBV) stake by 0.26% in Q1 2026, buying an estimated $14.6K and bringing the position to 25,204 shares worth $5.48M. The position accounts for 1.85% of the portfolio, ranked #9.
Front Row Advisors first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $5.9M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Front Row Advisors held 25,204 shares of AbbVie worth $5.48M as of Q1 2026.
- Front Row Advisors bought 66 AbbVie shares in Q1 2026, an estimated $14.6K.
- AbbVie made up 1.85% of Front Row Advisors's portfolio in Q1 2026, its #9 holding.
- Front Row Advisors first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Front Row Advisors's AbbVie position peaked at $5.9M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.